Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).

@article{Tubiana2005TherapeuticIW,
  title={Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).},
  author={Roland Tubiana and Guislaine Carcelain and Muriel Vray and Karine Gourlain and C{\'e}cile Dalban and Aziza Chermak and Claire Rabian and Daniel Vittecoq and Anne Simon and Elisabeth Bouvet and Raphaelle El Habib and Dominique Costagliola and Vincent Calvez and Brigitte Autran and Christine Katlama},
  journal={Vaccine},
  year={2005},
  volume={23 34},
  pages={4292-301}
}
This open single-arm study evaluated whether the administration of an HIV-recombinant canarypox vaccine (vCP1433) in highly active antiretroviral therapy (HAART)-treated patients chronically infected with HIV was safe, immunogenic and associated with prolongation of treatment discontinuation: 48 patients received four monthly vCP1433 injections and stopped… CONTINUE READING